Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.99, $0.09 better than the analyst estimate of $0.90. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $155.74 million.

GUIDANCE:

Today the company is providing full-year 2022 operating expense guidance as follows:

• Non-GAAP R&D expense of $75 million to $85 million;
• Non-GAAP SG&A expense of $220 million to $230 million; and
• Stock-based compensation of $40 million to $45 million

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.